Cargando…

Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn’s Disease Patients with Prescription Claims for Ustekinumab in the USA

BACKGROUND: Real-world evidence for how US Crohn’s disease (CD) patients use ustekinumab is limited. OBJECTIVES: The aim of this study was to describe the persistence, maintenance dosing, and pre-post corticosteroid and opioid use for CD patients in the USA treated with ustekinumab and those treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Zhijie, Obando, Camilo, Muser, Erik, Kozma, Chris, Slaton, Terra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605940/ https://www.ncbi.nlm.nih.gov/pubmed/34136998 http://dx.doi.org/10.1007/s40801-021-00264-5

Ejemplares similares

Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
por: Obando, Camilo, et al.
Publicado: (2020)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis
por: Banon, Tamar, et al.
Publicado: (2022)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Evaluation of Hylan G-F 20 Treatment with Opioid Prescriptions and Intraarticular Corticosteroid Injections in Patients with Osteoarthritis of the Knee Using a Claims Database
por: Langworthy, Michael J., et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease
por: Dubinsky, Marla, et al.
Publicado: (2023)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
por: Andres, Brendan, et al.
Publicado: (2022)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
por: Seo, Gi Hyeon, et al.
Publicado: (2023)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
por: Tuskey, Anne, et al.
Publicado: (2014)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
por: Mishra, Avantika, et al.
Publicado: (2018)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
por: Doornekamp, Laura, et al.
Publicado: (2020)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Disease
por: Globig, Anna-Maria, et al.
Publicado: (2020)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)

Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients
por: Mechie, Nicolae-Catalin, et al.
Publicado: (2021)

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
por: af Björkesten, Clas-Göran, et al.
Publicado: (2020)

Opioid Prescription Claims Among Women of Reproductive Age — United States, 2008–2012
por: Ailes, Elizabeth C., et al.
Publicado: (2015)

The association of prescription opioid use with suicide attempts: An analysis of statewide medical claims data
por: Luo, Chongliang, et al.
Publicado: (2022)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Accuracy of the days’ supply and the number of refills allowed recorded in Québec prescription claims databases for inhaled corticosteroids
por: Blais, Lucie, et al.
Publicado: (2014)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2017)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
por: Cohen, Alexandra, et al.
Publicado: (2021)

Ustekinumab-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn's Disease
por: Jordan, Ariel, et al.
Publicado: (2022)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease
por: Abi Doumeth, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r3ki63qbtqr1hlgvvbrefodqi4